Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Watchful As MDUFMA Implementation Proceeds

This article was originally published in The Silver Sheet

Executive Summary

IMPLEMENTATION OF NON-USER FEE MDUFMA PROVISIONS is moving forward as FDA continues to meet numerous deadlines required under the legislation: -- The agency has identified which "critical" reprocessed single-use devices will require 510(k) submissions in 2004 -- Enforcement of device branding provisions has been deferred until new guidance is issued -- FDA plans to be an advocate for electronic labeling -- Crafting a consistent policy for bundling premarket submissions may prove difficult -- An upcoming report is likely to recommend that CBER retain its device review authority -- Pediatric guidances address device design and clinical trial setup

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036078

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel